Neurizon Therapeutics:
A new horizon in neurodegenerative disease treatment

Science-led. Patient-driven. Globally connected.

Neurizon Therapeutics is an Australian late clinical-stage biotechnology company advancing investigational treatment for **Amyotrophic Lateral Sclerosis (ALS)** - also known as **Motor Neurone Disease (MND)**.

Our mission is simple yet meaningful: *To bring forward next-generation treatments that make a real difference in the lives of people affected by neurodegenerative diseases and their loved ones.* We are building more than a biotech company — we are creating a community united by science, compassion, and purpose.

Neurizon Therapeutics / Suite 2, Level 11, 385 Bourke Street, Melbourne VIC 3000, Australia
Email us: enquiries@neurizon.com / Call us: +61 (3) 9692 7222 / Website: www.neurizon.com

Neurizon

Our Lead ALS Investigational Therapy: **NUZ-001**

NUZ-001 is an investigational, **orally administered therapy** designed to address the root causes of ALS, not just its symptoms.

In preclinical studies, NUZ-001 has been shown to cross the blood–brain barrier and reach the central nervous system.

It is hypothesized that NUZ-001 may enhance the neurons natural protein-clearance systems: 'Autophagy' a pathway for clearing large protein aggregates and the 'Proteasomal' system which selectively clears smaller protein aggregates.

Together, these pathways play an important role in maintaining protein balance within neurons, also known as protein homeostasis. Supporting the activity of these systems may assist in the processing and clearance of aggregated and misfolded proteins.

Our Progress So Far

Phase 1 and Open-Label Extension Studies

NUZ-001 has completed a Phase 1 clinical study and subsequent 12-month open-label extension (OLE) in a cohort of people living with ALS in Australia. Several participants remain on treatment, with the longest-treated participant approaching four years of continuous exposure to NUZ-001.

Initial study results showed treatment appeared safe and generally well tolerated, with no treatment-related serious adverse events reported.

Top-line findings from the Phase 1 and OLE studies demonstrated encouraging trends across exploratory clinical measures, including survival, functional decline, and respiratory outcomes as well as across biomarker readings.

Phase 2/3 HEALEY ALS Platform Trial

Enrolment is now complete in Regimen I, with 250 participants enrolled across 78 U.S. clinical sites in less than five months from first participant dosing, making Regimen I the fastest regimen in the history of the HEALEY ALS Platform Trial to activate sites and complete enrolment.

Participants are progressing through the planned 36-week randomised treatment period, with topline efficacy and safety results expected in late Q2 CY2027.

Looking Ahead

With enrolment complete, the focus is now on completing the 36-week randomised treatment period and generating robust controlled clinical data for NUZ-001.

The completion of recruitment has removed a major source of clinical development execution risk, with topline efficacy and safety results expected in late Q2 CY2027.

Dr Chris Bremer has been appointed as Chief Executive Officer, effective 1 October 2026, bringing extensive global pharmaceutical and biotechnology experience as Neurizon enters its next stage of development.

Alongside our clinical activities, we will continue to engage with investigators and regulatory bodies, while building the scientific understanding of NUZ-001 and exploring its broader potential across neurodegenerative diseases.

Our Commitment to the ALS Community

Guided by our purpose and commitment to patients, we remain focused on delivering meaningful, science-driven progress and creating a new horizon in the treatment of neurodegenerative diseases.

Corporate Snapshot

Listings: ASX: NUZ | OTCQB: NUZTF
Shares on issue: ~784.2 million

Share price: A$0.056
Market capitalisation: ~A$44 million
Cash: A$12.7 million at 30 June 2026

R&D financing: Up to A$17.5 million facility secured against anticipated R&D Tax Incentive refunds

Updated September 2026

Together we can create hope by delivering meaningful progress for people living with ALS.

Neurizon